In vivo Quantitative Tomography of 225Ac Daughters in a Prostate Cancer Mouse Model with a Compton Camera

Cancer treatment is constantly searching for weapons that are precise enough to destroy a tumor without harming the patient. One promising approach involves using tiny packets of radioactive material that seek out cancer cells and release alpha particles, a type of radiation that acts like a microscopic sledgehammer. These particles travel only a very short distance, delivering a massive blow to the cancer cell while leaving the surrounding healthy tissue untouched. However, a significant problem arises once the radioactive material is inside the body. As the main radioactive atom decays, it breaks apart into smaller, moving pieces called daughter atoms. These pieces can recoil and detach from their original carrier, drifting away to settle in healthy organs like the kidneys or liver, potentially causing unintended damage. To make this therapy safe and effective, doctors need a way to watch exactly where these radioactive pieces go inside a living patient, but current imaging tools struggle to see them clearly at the tiny doses used for treatment.

A team of researchers has now demonstrated a new way to see these invisible travelers inside living mice. They used a specialized camera that does not rely on the heavy metal grids, or collimators, found in traditional medical scanners. Instead, this device uses a solid block of crystal that can detect the direction of gamma rays—tiny bursts of energy emitted as the radioactive atoms decay—by tracking how they bounce off electrons within the crystal. This method, known as Compton imaging, allows the camera to build a three-dimensional map of where the radiation is coming from without needing to block out most of the signal. The researchers applied this technique to a mouse model of prostate cancer that had been treated with a radioactive drug designed to target the tumor. They injected a very small amount of the drug, just 18.5 kBq, which is a dose low enough to be safe for a living animal but too faint for most standard scanners to detect.

The team scanned three mice, each carrying a small tumor, for thirty minutes while they lay still on a single platform. The camera successfully captured the gamma rays emitted by two specific daughter atoms, 221Fr and 213Bi, which are created as the main radioactive drug breaks down. By focusing on the specific energy signatures of these atoms, the researchers were able to reconstruct clear three-dimensional images showing where the radiation had accumulated. The results revealed that the radioactive drug had successfully traveled to the tumors, and the camera could distinguish the tumor from the rest of the body. Even though the tumors were small and the amount of radiation was incredibly low, the images showed the location of the cancer with surprising clarity. The researchers also measured the activity in the central organs, such as the liver and kidneys, which appeared as a single bright region in the images because the camera could not yet separate them from one another, but it could clearly tell the difference between the tumor and the rest of the body.

To ensure their new camera was telling the truth, the researchers compared the images they took inside the living mice with measurements taken after the mice were sacrificed. They removed the organs and tumors and counted the radiation in a laboratory machine. The numbers from the live images matched the numbers from the lab measurements almost perfectly. For the tumors, the camera detected between 86% and 98% of the actual radioactive activity present. This level of accuracy is significant because it proves that this new imaging method can provide a reliable, non-invasive way to track the drug and its dangerous byproducts in real time. The study shows that it is possible to visualize the movement of these radioactive daughters at doses that are relevant for actual human therapy, a feat that was previously thought to be impossible with such low levels of radiation.

The findings suggest that this technology could eventually help doctors optimize targeted alpha therapy by allowing them to watch how the drug behaves inside a patient over several days or weeks, rather than having to guess based on a single snapshot taken after the animal is killed. While the current system has limits, such as being unable to separate the individual organs in the center of the body, it successfully proved that a single detector can create a detailed 3D map of radioactive decay products in a living subject. This opens the door to better understanding how these powerful drugs distribute themselves in the body, which is a crucial step toward making alpha therapy a safer and more effective option for treating cancer in humans.